Capital Fund Management (CFM)
MRNA icon

Capital Fund Management (CFM)’s Moderna MRNA Stock Holding History

Capital Fund Management (CFM)’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.33M Sell
144,200
-615,400
-81% -$28.7M 0.03% 704
2025
Q4 		$22.4M Buy
759,600
+22,300
+3% +$606K 0.06% 449
2025
Q3 		$19M Sell
737,300
-1,255,900
-63% -$35M 0.05% 538
2025
Q2 		$55M Sell
1,993,200
-1,310,700
-40% -$34.5M 0.15% 185
2025
Q1 		$93.7M Buy
3,303,900
+1,317,000
+66% +$46.7M 0.27% 76
2024
Q4 		$82.6M Buy
1,986,900
+1,360,500
+217% +$65M 0.21% 126
2024
Q3 		$41.9M Buy
626,400
+30,200
+5% +$2.77M 0.11% 239
2024
Q2 		$70.8M Sell
596,200
-255,300
-30% -$32.3M 0.21% 124
2024
Q1 		$90.7M Sell
851,500
-316,700
-27% -$31.9M 0.26% 82
2023
Q4 		$116M Buy
1,168,200
+508,900
+77% +$42.8M 0.31% 51
2023
Q3 		$68.1M Buy
659,300
+304,700
+86% +$34M 0.24% 101
2023
Q2 		$43.1M Buy
354,600
+273,400
+337% +$36.5M 0.17% 147
2023
Q1 		$12.5M Sell
81,200
-72,800
-47% -$12M 0.06% 424
2022
Q4 		$27.7M Sell
154,000
-126,000
-45% -$20.6M 0.19% 145
2022
Q3 		$33.1M Sell
280,000
-47,400
-14% -$7.19M 0.26% 90
2022
Q2 		$46.8M Buy
327,400
+47,100
+17% +$6.73M 0.43% 37
2022
Q1 		$48.3M Sell
280,300
-47,000
-14% -$7.91M 0.39% 29
2021
Q4 		$83.1M Buy
327,300
+31,100
+10% +$9.09M 0.6% 11
2021
Q3 		$114M Sell
296,200
-114,600
-28% -$42.3M 0.84% 4
2021
Q2 		$96.5M Buy
410,800
+249,500
+155% +$44.6M 0.76% 8
2021
Q1 		$21.1M Buy
+161,300
New +$23.4M 0.23% 117

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Fund Management (CFM)'s MRNA Position: Q1 2026 in Review

Capital Fund Management (CFM) reduced its Moderna (MRNA) stake by 39% in Q1 2026, selling an estimated $17.1M and leaving 569,930 shares worth $29M. The position accounts for 0.13% of the portfolio, ranked #196.

Capital Fund Management (CFM) first reported a position in MRNA in Q2 2020 and has held it in 15 quarters since. The position peaked at $57M in Q4 2024. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Capital Fund Management (CFM) held 569,930 shares of Moderna worth $29M as of Q1 2026.
  • Capital Fund Management (CFM) sold 367,150 Moderna shares in Q1 2026, an estimated $17.1M.
  • Moderna made up 0.13% of Capital Fund Management (CFM)'s portfolio in Q1 2026, its #196 holding.
  • Capital Fund Management (CFM) first reported a position in Moderna in Q2 2020 and has held it in 15 quarters since.
  • Capital Fund Management (CFM)'s Moderna position peaked at $57M in Q4 2024.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.